Additional Information Regarding the Clarification Statement Released by Genomic Research Center, Academia Sinica on April 19, 2022


The CHO-V10, a second-generation universal COVID-19 vaccine, is a totally new vaccine design developed by CHO Pharma utilizing our patented technology platform, CHOptimaxTM. The exploratory research started in late 2020, and the initial findings showed CHO-V10 induced antibodies that could neutralize various SARS-CoV-2 variants. Encouraged by these results, the CHO-V10 was upgraded to an official research project of CHO Pharma in May 2021 and selected as “CDE can Help: COVID-19 special science counseling” by Center for Drug Evaluation (CDE) in the same month. So far, CHO-V10 has been through mice challenge studies and virus neutralization assay against major variants including the wild-type, the D614G, the British variant (a), the South African variant (b), the Brazil variant (g), the Indian variant (d), and the Omicron variant. The overall results are very promising, and the CHO-10V is now entering GMP production of clinical materials and GLP toxicity testing stage. Because the design of CHO-10V is closely related to the core technology of CHO Pharma, the success of CHO-V10 in human trials will greatly benefit our other universal vaccine developments on infectious diseases, such as flu and AIDS, and promotion of our CHOptimaxTM platform technology. There is no change regarding the schedule of clinical trials for CHO-V10.

CHO Pharma Inc. participated “2021 Industry Report: Vaccine and Drug Development in Taiwan”, a symposium hosted by Global Bio & Investment on September 15, 2021
The number of approved patents has doubled, with a total of 119 patents